Two-drug approach could overcome a common cancer mutation, make treatments more effective

Cancer cells are often a mess of mutations. About 20% to 25% of cancers involve mutations in a complex of molecules called SWI/SNF. Yet drugs designed to block SWI/SNF activity haven’t always worked as expected. Researchers at Harvard Medical School have now figured out why.

Leave A Comment

Your email address will not be published. Required fields are marked *